Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Christopher J. Sweeney(The University of Adelaide), David F. Jarrard(University of Wisconsin System), Mario A. Eisenberger(Johns Hopkins University), Manish Kohli(Mayo Clinic in Arizona), Daniel H. Shevrin(NorthShore University HealthSystem), Glenn Liu(University of Wisconsin Carbone Cancer Center), Elizabeth R. Plimack(Fox Chase Cancer Center), Joel Picus(Washington University in St. Louis), Maha Hussain(Northwestern University), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Yu‐Hui Chen(Dana-Farber Cancer Institute), Robert Dreicer(University of Virginia), Jorge A. García(Cleveland Clinic), Robert S. DiPaola(University of Kentucky), Noah M. Hahn(Johns Hopkins University), Matthew M. Cooney(University Hospitals Cleveland Medical Center), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center)
Cited by 1,105
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k